Format

Send to

Choose Destination
J Cell Mol Med. 2015 Sep;19(9):2253-61. doi: 10.1111/jcmm.12614. Epub 2015 Jun 17.

GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases.

Author information

1
Department of Neurosciences, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.
2
Department of Cancer Immunology of "Prof. dr. Ion Chiricuță" Oncologic Institute Cluj-Napoca, Cluj-Napoca, Romania.
3
Department of Statistics, Babes-Bolyai University Cluj-Napoca, Cluj-Napoca, Romania.
4
Department of Histology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.
5
"RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania.
6
Department of Biometry and Clinical Research, IDV Data Analysis and Study Planning, Krailling, Germany.
7
Department of Microbiology and Epidemiology, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.

Abstract

We studied whether the serum levels of glial fibrillary acidic protein (GFAP) and of antibodies against the N-methyl-d-aspartate receptor subunit NR2 (NR2 RNMDA ) can discriminate between intracerebral haemorrhage (ICH) and ischaemic stroke (IS) in stroke patients. We prospectively recruited patients with suspected stroke (72 confirmed) and 52 healthy controls. The type of brain lesion (ICH or IS) was established using brain imaging. The levels of GFAP and of antibodies against NR2 RNMDA were measured in blood samples obtained within 12 hrs after stroke onset and 24, 48 and 72 hrs and 1 and 2 weeks later using ELISA immunoassay. Improvement in diagnostic performance was assessed in logistic regression models designed to predict the diagnosis and the type of stroke. GFAP peaks early during haemorrhagic brain lesions (at significantly higher levels), and late in ischaemic events, whereas antibodies against NR2 RNMDA have significantly higher levels during IS at all time-points. Neither of the two biomarkers used on its own could sufficiently discriminate patients, but when they are used in combination they can differentiate at 12 hrs after stroke, between ischaemic and haemorrhagic stroke with a sensitivity and specificity of 94% and 91%, respectively.

KEYWORDS:

GFAP; NMDA; intracerebral haemorrhage; ischaemic stroke; neuronal biomarkers

PMID:
26081945
PMCID:
PMC4568929
DOI:
10.1111/jcmm.12614
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center